DK1192185T3 - Apo-2L-receptoragonist og CPT-11-synergisme - Google Patents

Apo-2L-receptoragonist og CPT-11-synergisme

Info

Publication number
DK1192185T3
DK1192185T3 DK00941233T DK00941233T DK1192185T3 DK 1192185 T3 DK1192185 T3 DK 1192185T3 DK 00941233 T DK00941233 T DK 00941233T DK 00941233 T DK00941233 T DK 00941233T DK 1192185 T3 DK1192185 T3 DK 1192185T3
Authority
DK
Denmark
Prior art keywords
cpt
apo
synergism
receptor agonist
methods
Prior art date
Application number
DK00941233T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Ralph H Schwall
Mark C Benyunes
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1192185T3 publication Critical patent/DK1192185T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK00941233T 1999-06-09 2000-06-07 Apo-2L-receptoragonist og CPT-11-synergisme DK1192185T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13824099P 1999-06-09 1999-06-09

Publications (1)

Publication Number Publication Date
DK1192185T3 true DK1192185T3 (da) 2006-10-23

Family

ID=22481115

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00941233T DK1192185T3 (da) 1999-06-09 2000-06-07 Apo-2L-receptoragonist og CPT-11-synergisme

Country Status (13)

Country Link
US (3) US20040228868A1 (da)
EP (1) EP1192185B1 (da)
JP (1) JP2003505344A (da)
AT (1) ATE330972T1 (da)
AU (1) AU5596500A (da)
CA (1) CA2375149A1 (da)
DE (1) DE60028971T2 (da)
DK (1) DK1192185T3 (da)
ES (1) ES2267547T3 (da)
IL (1) IL146491A0 (da)
PT (1) PT1192185E (da)
WO (1) WO2000075191A2 (da)
ZA (1) ZA200002867B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1624128A (zh) 1997-03-17 2005-06-08 人类基因组科学公司 包含死亡结构域的受体－5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
WO2000066156A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
PT1303293E (pt) * 2000-07-27 2009-03-11 Genentech Inc Administração sequencial de cpt-11 e polipéptido apo-2l
RU2287534C2 (ru) 2000-10-20 2006-11-20 Тугаи Сейяку Кабусики Кайся Деградированное антитело, являющееся агонистом tpo
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
CN100506277C (zh) * 2001-11-01 2009-07-01 Uab研究基金会 肿瘤坏死因子相关细胞凋亡诱导配体受体的选择性抗体和其它治疗剂的联合体系
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
ES2351786T3 (es) 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
CA2471140A1 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
CN101972478B (zh) * 2002-10-08 2012-10-31 免疫医疗公司 抗体治疗
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
WO2005056605A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha ３量体以上の受容体を認識する改変抗体
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
KR101292961B1 (ko) 2005-02-02 2013-08-02 더 유에이비 리서치 파운데이션 아폽토시스-유도 사멸 수용체 작용제에 대한 내성을 감소시키는데 관련된 약제 및 방법
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
NZ610153A (en) * 2010-10-29 2014-07-25 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
US20140178398A1 (en) 2011-05-03 2014-06-26 Genentech, Inc Vascular disruption agents and uses thereof
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
DE112013003864B4 (de) * 2012-08-03 2023-12-14 Mazda Motor Corporation Transparente Schichtstruktur und Verfahren zum Herstellen derselben
MA43365A (fr) 2015-12-01 2018-10-10 Genmab Bv Anticorps anti-dr5 et procédés d'utilisation de ceux-ci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
EP0981618B2 (en) * 1997-05-15 2011-08-24 Genentech, Inc. Anti-apo-2 antibody
AU8784498A (en) * 1997-08-15 1999-03-08 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
AU2338299A (en) * 1998-01-26 1999-08-09 Genentech Inc. Antibodies to death receptor 4 (dr4) and uses thereof
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002069995A2 (en) * 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer

Also Published As

Publication number Publication date
US20040228868A1 (en) 2004-11-18
EP1192185B1 (en) 2006-06-21
PT1192185E (pt) 2006-11-30
DE60028971D1 (de) 2006-08-03
ATE330972T1 (de) 2006-07-15
DE60028971T2 (de) 2007-02-08
WO2000075191A3 (en) 2001-05-10
WO2000075191A2 (en) 2000-12-14
ES2267547T3 (es) 2007-03-16
JP2003505344A (ja) 2003-02-12
IL146491A0 (en) 2002-07-25
US20070026000A1 (en) 2007-02-01
EP1192185A2 (en) 2002-04-03
AU5596500A (en) 2000-12-28
US20090041788A1 (en) 2009-02-12
ZA200002867B (en) 2001-12-07
CA2375149A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
DK1192185T3 (da) Apo-2L-receptoragonist og CPT-11-synergisme
CY1108815T1 (el) Διαδοχικη χορηγηση cpt-11 και πολυπεπτιδιου apo-2l
ATE398464T1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
AP2002002458A0 (en) Compounds for the treatment of ischemia.
EA200101166A1 (ru) Ингибиторы металлопротеаз
NO20052922L (no) Fremgangsmate og sammensetninger for induksjon av apoptosis hos cancerceller
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
NO20003600L (no) Kalium kanal inhibitorer
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
JO2356B1 (en) N-by-phenyl derivatives (methyl substituted) amino cycloalkan carboxamide
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
SE9900961D0 (sv) Novel compounds
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
SE9802208D0 (sv) Novel compounds
ATE327973T1 (de) Polyamin-analoge als cytotoxische wirkstoffe
TW200738288A (en) Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
SE9802209D0 (sv) Novel compounds
WO2002066415A3 (en) Non-steroidal modulators of estrogen receptors
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento